Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 09, 2023 03:01 ET | Source: Genmab A/S

Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023

Media ReleaseCOPENHAGEN, Denmark; June 9, 2023, at 9:00am CEST Results from phase 1/2 EPCORE™ NHL-2 trial investigating epcoritamab in combination with rituximab-lenalidomide (R2) showed a 98...
June 08, 2023 17:22 ET | Source: Genmab A/S

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; June 8, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 7,825 restricted stock units and 8,106 warrants to employees of the...
June 06, 2023 02:00 ET | Source: Genmab A/S

Genmab to Participate in a Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference

Media Release COPENHAGEN, Denmark; June 6, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Goldman Sachs 44th...
June 01, 2023 15:40 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; June 1, 2023 – Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this...
May 31, 2023 08:15 ET | Source: Genmab A/S

Transactions with Shares and Linked Securities in Genmab A/S Made By Managerial Employees and Their Closely Associated Persons

Company Announcement COPENHAGEN, Denmark; May 31, 2023 – Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this...
May 25, 2023 17:10 ET | Source: Genmab A/S

Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress

Media ReleaseCOPENHAGEN, Denmark; May 25, 2023 Oral presentations will highlight epcoritamab-bysp in combination with rituximab-lenalidomide (R2) in high-risk follicular lymphomaPoster presentations...
May 23, 2023 15:14 ET | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; May 23, 2023 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 33,098 shares as a consequence of the exercise of employee warrants. The...
May 19, 2023 12:33 ET | Source: Genmab A/S

EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

Company Announcement Results from phase 2 clinical trial demonstrated EPKINLY™ (epcoritamab-bysp) delivered 61 percent overall response rate, 38 percent complete response, and 15.6-month median...
May 10, 2023 11:01 ET | Source: Genmab A/S

Genmab Announces Financial Results for the First Quarter of 2023

May 10, 2023 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2023 Highlights Genmab revenue increased 35% compared to the first quarter of 2022, to DKK 2,854 million “In...
April 24, 2023 04:39 ET | Source: Genmab A/S

Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen

Company Announcement COPENHAGEN, Denmark; April 24, 2023 – Genmab A/S (Nasdaq: GMAB) announced today its decision to file a request for review of the award dismissing its claims in the second...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right